Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors
Inhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using f...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Sensors |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8220/21/14/4814 |
id |
doaj-40fa4410d8ef4dd5a5d113c960266034 |
---|---|
record_format |
Article |
spelling |
doaj-40fa4410d8ef4dd5a5d113c9602660342021-07-23T14:05:51ZengMDPI AGSensors1424-82202021-07-01214814481410.3390/s21144814Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated BiosensorsShira Roth0Amos Danielli1Faculty of Engineering, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Max and Anna Webb Street, Ramat Gan 5290002, IsraelFaculty of Engineering, The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Max and Anna Webb Street, Ramat Gan 5290002, IsraelInhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using fluorescently and magnetically modulated biosensors (MMB), we developed a rapid and sensitive inhibitor screening tool. This study demonstrates its performance by screening small molecules and neutralizing antibodies as potential inhibitors of the interaction between the spike protein 1 (S1) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the angiotensin-converting enzyme 2 (ACE2) receptor. The MMB-based assay is highly sensitive, has minimal non-specific binding, and is much faster than the commonly used ELISA (2 h vs. 7–24 h). We anticipate that our method will lead to a remarkable advance in screening for new drug candidates.https://www.mdpi.com/1424-8220/21/14/4814magnetically aggregated biosensorsinhibitor screeningSARS-CoV-2spike proteinangiotensin-converting enzyme 2neutralizing antibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shira Roth Amos Danielli |
spellingShingle |
Shira Roth Amos Danielli Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors Sensors magnetically aggregated biosensors inhibitor screening SARS-CoV-2 spike protein angiotensin-converting enzyme 2 neutralizing antibodies |
author_facet |
Shira Roth Amos Danielli |
author_sort |
Shira Roth |
title |
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors |
title_short |
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors |
title_full |
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors |
title_fullStr |
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors |
title_full_unstemmed |
Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors |
title_sort |
rapid and sensitive inhibitor screening using magnetically modulated biosensors |
publisher |
MDPI AG |
series |
Sensors |
issn |
1424-8220 |
publishDate |
2021-07-01 |
description |
Inhibitor screening is an important tool for drug development, especially during the COVID-19 pandemic. The most used in vitro inhibitor screening tool is an enzyme-linked immunosorbent assay (ELISA). However, ELISA-based inhibitor screening is time consuming and has a limited dynamic range. Using fluorescently and magnetically modulated biosensors (MMB), we developed a rapid and sensitive inhibitor screening tool. This study demonstrates its performance by screening small molecules and neutralizing antibodies as potential inhibitors of the interaction between the spike protein 1 (S1) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the angiotensin-converting enzyme 2 (ACE2) receptor. The MMB-based assay is highly sensitive, has minimal non-specific binding, and is much faster than the commonly used ELISA (2 h vs. 7–24 h). We anticipate that our method will lead to a remarkable advance in screening for new drug candidates. |
topic |
magnetically aggregated biosensors inhibitor screening SARS-CoV-2 spike protein angiotensin-converting enzyme 2 neutralizing antibodies |
url |
https://www.mdpi.com/1424-8220/21/14/4814 |
work_keys_str_mv |
AT shiraroth rapidandsensitiveinhibitorscreeningusingmagneticallymodulatedbiosensors AT amosdanielli rapidandsensitiveinhibitorscreeningusingmagneticallymodulatedbiosensors |
_version_ |
1721285968900653056 |